Epicrispr Biotechnologies
Epicrispr Biotechnologies, Inc.
Epicrispr Biotechnologies
epicrispr.com · South San Francisco, CA
Funding event
The round itself, as filedInferred stageSeries C+
Sold of offered$177M of $213M
Filed2026-08-26
Days since filing38
- Exemption claimed
- Rule 506(b)
- First-ever Form D
- Yes
- Date of first sale
- 2018-05-04
Investors
No investors named: Form D does not list them
Officers on the filing
Names and roles as filed; addresses are never stored- Amber SalzmanExecutive Officer · Director
- Haorui ZhangExecutive Officer · Director
- Lei QiDirector
- Andrew LamDirector
- Jennifer KingDirector
- Eric CrombezDirector
- Anran LiDirector
Health flags
Three flags, each with the raw inputs behind it · as of 2026-10-03UndersubscribedNot flagged83.1% sold101 months since first sale
Prior raiseNot flaggedPrior raise not known—
AmendedNot flaggedNo amendmentNo D/A on file
Open roles
On the employer's own careers page · checked 2026-09-210
Pre-posting windowNot enough dataShown once this sector and stage have 20 observed lags from filing to first posting.
No open roles foundWe read careers pages daily.
Also raised in Health & bio
Same sector, 28 days to 2026-10-04Altay TherapeuticsSeries A · $15.7M of $45.1M · San Carlos, CAQuietCarebilitySeries A · $8.8M of $8.8M · Richardson, TXQuiet
75 rounds in Health & bio in the 28 days to 2026-10-02, against 71 in the 28 days before.